2022EASD前瞻｜35项中国研究亮相国际会场
2022-09-16 14:35:47来源：医脉通阅读：13次
导读：2022年9月19日~23日，一年一度的内分泌学术盛宴——2022年欧洲糖尿病研究协会第58届年会（EASD）将于瑞典斯德哥尔摩隆重举行。
据日前大会公布的日程，诸多中国学者的研究亮相大会主报告、口头报告，涉及糖尿病基础研究、药物研究及临床试验等，本文将呈现本次会议所有来自中国学者的研究，以飨读者。
报告1：OP 01-植物膳食与中国成年人
The association between plant-based diet indices and obesity and metabolic diseases in Chinese adults: longitudinal analyses from the China Health and Nutrition survey
报告人：B. Chen, J. Zeng, M. Qin, W. Xu, Z. Zhang, X. Li, S. Xu
报告2：OP 07-
Empagliflozin attenuates obesity-related kidney dysfunction and NLRP3 inflammasome activity through the HO-1/adiponectin axis
报告人：T. Ye, J. Zhang, J. Shi, C. Kan, F. Han, N. Hou, X. Sun
报告3：OP 11-Mir-15b通过靶向胰岛素受体介导肥胖诱导的脂肪细胞胰岛素抵抗
Mir-15b mediates the obesity-induced adipocyte insulin resistance by targeting insulin receptor
报告人：L. Xingjing
报告4：OP 11-通过人类内脏脂肪组织的单细胞RNA测序鉴定健康和肥胖
Single-cell RNA sequencing of human visceral adipose tissue identifies new macrophage clusters in health and obese type 2 diabetes
报告人：Y. Yuan, H. Wang, H. Sun, Y. Bi
报告5：OP 13-糖尿病前期人群的进展和转归：一项3年随访研究
Novel clusters of prediabetes and their association with progression and regression: a 3-year follow-up study
报告人：Y. Liu, M. Sang, S. Qiu, Z. Sun
报告6：OP 19-GLP-1与胆囊或胆道疾病：数据来自FDA不良事件报告系统
Glucagon-like peptide 1 receptor agonists and gallbladder or biliary diseases: data from the FDA Adverse Event Reporting System
报告人：H. Zhang, L. He, J. Wang, N. Yang, W. Li, L. Xu, Y. Li, F. Ping
报告7：OP 30-微球生物人工胰岛与β细胞和间充质干细胞共包封治疗糖尿病
Microsphere-based bioartificial islet with beta cells and mesenchymal stem cells co-encapsulation for diabetes treatment
报告人：J. Sun, L. Li
报告8：OP 31-
Efficacy of metformin in preventing progression to diabetes in Chinese subjects with impaired glucose regulation: results from a multicentre, open-label RCT
报告人：L. Zhang, Y. Zhang, S. Shen, X. Wang, Q. Li, L. Ji, N. Sun, G. Li, CDPP study group
报告9：OP 33-Glp-1/gdf15双激动剂治疗小鼠和非人灵长类动物的肥胖和高血糖
Glp-1/gdf15 dual agonist to treat obesity and hyperglycaemia in mice and non-human primates
报告人：Y.Y. Zhang, A. Kharitonenkov, X.Y. Zhao, X.N. Dong, Y.Y. Zhang, H.X. Zou, Y.G. Jin, W. Guo, P. Zhai, X. Chen
报告10：SO 03-喝茶与2型糖尿病风险：一项队列研究、最新系统综述和剂量反应荟萃分析
Tea consumption and the risk of type 2 diabetes: a cohort study and updated systematic review and dose-response meta-analysis
报告人：X. Li, J. Zeng, B. Chen, Q. Yan, Y. Cui, W. Xu, X. Zhang, S. Xu
报告11：SO 03-GABA和西他列汀预防高脂饮食引起的β细胞功能损害
GABA and sitagliptin prevent impairment of beta cell function caused by high-fat diet
报告人：Z. Wang, L. Fan, Y. Ni, A. Ma, D. Wu, Y. Zhao, J. Li, Q. Cui, Y. Zhou, L. Zhang, Y.-R. Lou, G. Prud’homme, Q. Wang
报告12：SO 11-中国人群的夜盲症和糖尿病风险：一项多中心、横断面研究
Night blindness and risk of diabetes in the Chinese population: a multi-centre, cross-sectional study
报告人：J. Wang, Y. Liu, Y. Zhou, Y. Ding, S. Qiu, Z. Sun
报告13：SO 11-胆囊切除术与血糖异常的相关性：一项横断面和前瞻性分析
Association between cholecystectomy and dysglycaemia: cross-sectional and prospective analyses
报告人：M. Sang, C. Xie, Y. Liu, S. Qiu, X. Wang, Z. Sun, T. Wu
报告14：SO 13-在TIR超过70%的2型糖尿病患者中，CGM衍生指标与
Relationships between CGM-derived metrics and risk factors for hypoglycaemia among patients with type 2 diabetes with TIR more than 70%
报告人：J. Lu, D. Chen, W. Xu, D. Yang, Z. Liu, B. Lin
报告15：SO 13-应激性高血糖与
Stress hyperglycaemia is associated with an increased risk of post-acute pancreatitis diabetes
报告人：J. Zhang, Y. Lv, L. Li
报告16：SO 15-胰腺δ细胞通过抑制α细胞的内源性
Pancreatic delta cells switched islet Ca2+oscillation modes by inhibiting endogenous glucagon from alpha cells
报告人：H. Ren, Y. Li, Y. Yu, T. Chang, W. Qian, X. Yang, L. Chen, C. Tang
报告17：SO 15-三维成像显示胰岛中钙波的保守模式
Three-dimensional imaging reveals conserved patterns of calcium wave in the pancreatic islet
报告人：Y. Yu, H. Ren, Y. Li, X. Yang, L. Chen, C. Tang
报告18：SO 17-CLEC11A在人胰岛和人内分泌βH1细胞中的表达和功能
The expression and function of CLEC11A in human pancreatic islets and human EndoC-βH1 cells
报告人：J. Cen, R. Shi, G. Westermark, Z. Sun, N. Welsh, J. Lau, Sweden
报告19：SO 21-紫苏脂素2通过恢复胰岛星状细胞静止来保护脂毒性诱导的胰岛纤维化
Perilipin 2 protects against lipotoxicity-induced islet fibrosis by restoring islet stellate cells quiescence
报告人：Y. Zhou, H. Wang, Y. Wang, Z. Sun, J. Ma
报告20：SO 32-在C57BL/6雄性小鼠中，SGLT2抑制可防止高脂饮食诱导的
SGLT2 inhibition prevents high fat diet-induced glucose intolerance, but not weight gain, in C57BL/6 male mice
报告人：T. Li, W. Zhu, Z. Sun, C. Rayner, R. Young, T. Wu
报告21：SO 35-肥胖和抑郁之间的关系部分取决于代谢状态：一项全国住院患者样本数据库研究
The relationship between obesity and depression is partly dependent on metabolic status: a nationwide inpatient sample database study
报告人：Z. Wang, J. Zhao, X. Fan
报告22：SO 36-Irisin通过调节肥胖小鼠肾周脂肪组织功能来预防肥胖相关肾脏疾病
Irisin protects against obesity-related kidney disease by regulating perirenal adipose tissue function in obese mice
报告人：X. Sun, F. Han, C. Kan, N. Hou
报告23：SO 38-中国老年2型糖尿病患者服用
Real-world safety of dapagliflozin in elderly patients with type 2 diabetes in China: post-hoc analysis of the DONATE study
报告人：L. Guo, J. Wang, L. Li, L. Yuan, S. Chen, H. Wang, T. Li, L. Qi, H. Yang
报告24：SO 45-在
Post-prandial glucose reduction with YG1699 compared to dapagliflozin in subjects with type 1 diabetes
报告人：P. Lapuerta, S. Urbina, A. Wittle, J. He, C. Li, T. Li
报告25：SO 45-二肽基肽酶-4抑制剂与2型糖尿病胆囊或胆道疾病：随机对照试验的系统回顾和荟萃分析
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and meta-analysis of randomised controlled trials
报告人：L. He, J. Wang, N. Yang, L. Xu, W. Li, F. Ping, J. Huang, Y. Li, H. Zhang
报告26：SO 59-中国2型糖尿病患者血清25-羟基
Serum 25-hydroxyvitamin D levels in relation to the risk of peripheral neuropathy in Chinese patients with type 2 diabetes
报告人：Y. Yang, J. Wang, Y. Ding, L. Zhang
报告27：SO 61-预测
Nomogram model for predicting the risk of sepsis in diabetic foot patients
报告人：P. Huang, X. Zhao, Y. Gu
报告28：SO 62-HMGB1抑制保护Schwann 细胞免受高糖诱导的细胞毒性
HMGB1 inhibition protects Schwann cells from high glucose-induced cytotoxicity
报告人：M. Shi, J. Song, X. Zheng, Y. Chen, W. Gu, H. Zhang
报告29：SO 63-血糖和c肽峰值时间与2型糖尿病患者的慢性并发症相关
Glucose and c-peptide peak times are associated with chronic complications in patients with type 2 diabetes
报告人：Q. Jiang, X.L. Wang, X.Q. Zhao, Y. Sun, P. Huang, S.H. Ji, R.Y. Hu, Y.J. Gu
报告30：SO 68-抑制NLRP3改善糖尿病相关认知功能障碍中的脂质累积
Inhibition of NLRP3 ameliorates lipid accumulation in diabetic-associated cognitive dysfunction
报告人：W. Zhu, T. Niu, T. Li, H. Zhang, S. Wang
报告31：SO72-GlcN酰化通过抑制nf-Kb p65/nlrp3炎症信号传导途径减轻AGE诱导的神经炎症
O-glcnacylation attenuated ages-induced neuroinflammation by inhibiting nf-Κb p65/nlrp3 inflammatory signalling pathway
报告人：T. Niu, W. Zhu, H. Zhang, S. Wang
报告32：SO 74-无论2型糖尿病患者的久坐时间如何，高水平的体力活动与
High levels of physical activity are associated with a reduced risk of CVD regardless of sedentary time among type 2 diabetes patients
报告人：Y. Wu, W. Wang, J. Zhao, The MIDiab Study Group
报告33：SO 75-通过连续血糖监测评估的血糖变异性增加与2型糖尿病患者骨质疏松症相关
Increased glycaemic variability evaluated by continuous glucose monitoring is associated with osteoporosis in type 2 diabetes patients
报告人：R. Huang, H. Wang, Z. Shen, T. Cai, Y. Zhou, Y. Wang, J. Wu, J. Ma
报告34：SO 77-不同肥胖程度受试者内脏脂肪细胞大小与
Association between visceral adipocyte size and non-alcoholic fatty liver disease in subjects with different degrees of adiposity
报告人：H. Sun, T. Gu, D. Fang, Y. Yuan, H. Wang, Y. Bi
报告35：SO 77-非酒精性脂肪肝是急性胰腺炎后新发糖尿病的独立危险因素
Non-alcoholic fatty liver disease (
报告人：Y. Lv, J. Zhang, T. Yang, L. Li